Update on the use of rituximab for intractable rheumatoid arthritis.

Open Access Rheumatol · 2009 · PMC5074725 · PMID 27789983

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Benefits from a single course of rituximab were highly significant at 24 weeks and persisted at 48 weeks especially in the group that received methotrexate.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.